An electrochemical SARS-CoV-2 biosensor inspired by glucose test strip manufacturing processes†

Vincent J. Vezza, Adrian Butterworth, Perrine Lasserre, Ewen O. Blair, Alexander MacDonald, Stuart Hannah, Christopher Rinaldi, Paul A. Hoskisson, Andrew C. Ward, Alistair Longmuir, Steven Setford, Eoghan C. W. Farmer, Michael E. Murphy and Damion K. Corrigan

Accurate and rapid diagnostic tests are critical to reducing the impact of SARS-CoV-2. This study presents early, but promising measurements of SARS-CoV-2 using the ACE2 enzyme as the recognition element to achieve clinically relevant detection. The test provides a scalable route to sensitive, specific, rapid and low cost mass testing.

SARS-CoV-2 came to the attention of health authorities during late 2019, shortly followed by declaration of a “public health emergency of international concern” on 30th of January 2020. SARS-CoV-2 quickly spread around the globe and was declared a pandemic by the World Health Organisation on 11th of March 2020. The virus, SARS-CoV-2, is the aetiological agent of coronavirus disease (Covid-19). Diagnostics have been a major priority and challenge thus far in the pandemic with assay quantity, reagent costs and time to result being of prime concern. SARS-CoV-2 has four major structural proteins, with the spike protein known to bind to the surface of cells expressing angiotensin converting enzyme 2 (ACE2) on their surface. The affinity between ACE2 and the spike protein is shown to be in the low nanomolar range giving a similar level of affinity to an antibody-antigen interaction. The enzyme represents an important candidate molecule for construction of a biosensor because of the high affinity between the spike protein and ACE2 and the fact that a limited number of coronaviruses utilise ACE2 for entry (SARS-CoV-1, SARS-CoV-2 and HCoV-NL63) HCoV-NL63 causes infection primarily in young children, has a lower overall affinity for ACE2 (3–10 times lower) and is a pathogen responsible for only mild/moderate childhood disease. It is therefore possible for ACE2 to be deployed as a selective receptor in various biosensor formats for this crucial category of human respiratory pathogen, either to allow definitive diagnosis of SARS-CoV-2 in adults or as a screening tool for identifying positive cases, which then receive confirmatory lab testing. Finally, the ACE2 enzyme is a carboxypeptidase responsible for the hydrolytic cleavage of angiotensin II to angiotensin [1,7] liberating phenylalanine in the process. The active site is positioned away from SARS-CoV-2 binding site meaning that enzyme activity and binding from other proteins or small molecules in human samples is likely to be insignificant when compared to binding of an entire SARS-CoV-2 viral particle (50–200 nm) and the resulting effect on electrochemical signal. A critical feature of the ACE2 enzyme is the hydrophobic region which normally facilitates insertion into cell membranes and allows ACE2 insertion into a synthetically made amphiphobic structures resembling cell membranes.

The fluorous effect is a well-known and well described tendency for fluorine atoms to avoid unfavoured interactions with other elements. Formation of fluorous self-assembled monolayers (SAMs) have been utilised in organic electronics to reduce biological fouling of surfaces. Here, a perfluorocarbon SAM formed of 1H,1H,2H,2H-Perfluorodecanethiol (PFDT) is deployed on a gold sensor surface to form a layer of amphiphobic character which facilitates straightforward insertion of ACE2 via its hydrophobic tail (ordinarily employed for membrane insertion in vivo). Use of a perfluorocarbon SAM with its unique properties provided a robust combination of anti-biofouling behaviour and enzyme insertion, allowing straightforward sensor preparation.

Electrochemical biosensors offer a very attractive route to sensitive and low cost detection of biological analytes. The most
notable example of this is the glucose biosensor, operating via the glucose oxidase enzyme which is in widespread use each day by diabetic patients for routine determination of blood glucose levels. As a result of demand, facilities exist with very high volume manufacturing capability (e.g. several million sensors per day) and very well characterised chemical layer and enzyme deposition protocols. Due to the volume of sales in the glucose market (similar demand would exist for Covid-19 screening) unit costs of 20 UK pence can be achieved using established manufacturing processes. Very few diagnostic technologies, including lateral flow assays, can currently compete from a cost and volume perspective (e.g. current lateral flow Covid-19 assays cost £5–20 per test in the UK). In contrast, the sensor presented here requires a simple two stage preparation procedure of (1) PFDT deposition on a low cost PCB electrode and (2) ACE2 functionalisation through physisorption into the PFDT (Scheme 1). These steps are compatible with current manufacturing practices for glucose biosensors and importantly provide opportunity to rapidly translate the approach described here for SARS-CoV-2 detection into a glucose test strip production environment. This unlocks potential to achieve an extremely low cost Covid-19 assay, which utilises already CE marked substrates and approved assay readers, thus minimising the regulatory burden. Additionally, the assay is mutation proof as it exploits the interaction between SARS-CoV-2 spike protein and ACE2, has a degree of in-built surface orientation through the ability of ACE2 to insert via its hydrophobic region and offers the opportunity to develop similar tests for other respiratory viruses entering cells via membrane bound surface proteins.

PFDT-SAM and ACE2 functionalisation experiments were performed on a PCB sensor array bearing eight gold working electrodes. Such PCB arrays are low cost and allow high throughput assay development and represent an excellent test bed for this assay. When functionalised with PFDT and ACE2, the charge transfer resistance ($R_{CT}$) of the $[\text{Fe(CN)}_6]^{3/4-}$ redox reaction, a signal parameter commonly used in impedimetric biosensor measurements, increased as expected (Fig. S1, ESI†). The PFDT SAM layer caused an increase in $R_{CT}$ and a further increase was noted when ACE2 was physisorbed into the PFDT layer, confirming successful insertion of the enzyme. This was in contrast to experiments on facile ACE2 insertion with thiolated-hydrocarbon layers, where ACE2 insertion behaviour and sensor performance was not reproducible (Fig. S2, ESI†).

To characterise the sensitivity and specificity of the sensor, experiments to assess dose response behaviour and determine specificity of the ACE2 spike protein interaction were conducted using recombinant spike protein, streptavidin and IL-6. IL-6, which is found at elevated levels in Covid-19 patients, and streptavidin, widely used in bioassays, were employed as negative controls. A clear dose response effect was found for recombinant spike-protein binding to ACE2 (Fig. 1). Fitting the dose response curve gave a limit of detection for recombinant spike protein of 1.68 ng mL$^{-1}$. The binding between ACE2 and spike protein at 100 ng mL$^{-1}$ was shown to be significantly different to IL-6 (100 ng mL$^{-1}$, $P = 3.158E-7$) and streptavidin (200 ng mL$^{-1}$, $P = 3.981E-4$) binding. This suggests it was possible to construct a sensitive and selective sensor operating on the principle of ACE2-spike glycoprotein interactions. Note – example Nyquist plots, equivalent circuit and representative values are shown in Fig. S3 (ESI†).

Next, assay performance in more complex samples was explored. Due to biosafety restrictions, the sensor was tested with inactivated virus samples at different concentrations alongside a negative sample from a commercial kit. All samples were provided in viral transport medium which contains proteins and dead eukaryotic cells used to culture the virus and was an appropriate proxy for a complex human tissue such as saliva. Furthermore, these kits are used to validate diagnostic tests in clinical biomedical laboratories because of their close resemblance to clinical samples. When a viral dose response curve was constructed, it was possible to detect the inactivated virus with increasing concentration (Fig. 2). Curve fitting and comparison to blank solution yielded an LoD of 38.6 copies mL$^{-1}$. At 10$^4$ and 10$^5$ copies mL$^{-1}$, the impedance change was significantly different to the negative control ($P = 0.004$ and $P = 6.765E-4$ respectively). The background signal increase observed in the negative control is most likely due to
residual non-specific surface interactions from the complex
viral sample medium (proteins, cellular debris etc.). To provide
context, RNA levels for SARS-CoV-2 in saliva samples have been
estimated in the range of $10^2-10^{13}$ copies per mL$^{10,11}$ Therefore,
these findings show it was possible to detect inactivated
SARS-CoV-2 from a complex sample in 30 minutes at clinically
relevant detection levels. Coupling this to the sensor being
designed for manufacture in mass production environments, it
raises the possibility of developing a Covid-19 assay using
established sensors and instrumentation from the blood glu-
cose industry.

To assess performance of the sensor more comprehensively,
two human saliva samples were tested in bio secure conditions.
One SARS-CoV-2 positive human saliva sample, confirmed
through PCR based clinical diagnostics (Ct = 26 cycles, indicating
high viral load), was transferred into inactivation solution called
VPSS containing a proprietary cell culture medium and Triton-X
(to denature the viral envelope whilst leaving proteins largely
intact). This was compared against a negative human saliva
sample (confirmed via PCR) which had undergone the same
handling processes as the positive sample. To carry out this
experiment an improved assay protocol was used. Firstly, the
positive and negative samples were premixed with ACE2 and then
allowed to physiosorb onto the PFDT modified sensor surface with a
measurement taken immediately after sample addition. This
increased the practicality of the assay by accelerating time to
result and has the potential to make storage, transport easier and
shelf life longer because sensor strips can be shipped without the
ACE2 enzyme being preprinted. Secondly, the clinical samples
were tested in VPSS medium. Once inactivated in VPSS, suspected
SARS-CoV-2 positive samples can be manipulated at Biosafety
Level 2 in contrast to untreated patient samples, or samples in
Viral Transport Medium (VTM), which require Biosafety Level 3
facilities. The ability to detect SARS-CoV-2 in VPSS using the
biosensor reported here means that as well as for self testing,
the assay is compatible with more centralised testing facilities
where it is important to protect an operator running multiple
samples such as hospital wards, GP surgeries, care homes, air-
ports and workplaces. Adopting this revised approach, the $R_{CT}$
changes in the positive and negative samples were found to be
significantly different (Fig. 3, $P = 1.2 \times 10^{-7}$). Changes to the assay
approach with clinical samples resulted in an apparent drop in
$R_{CT}$. This is attributed to a baseline artefact caused by Triton-X
and sensor surface interactions in VPSS. Further investigation is
being performed to fully understand and quantify these effects.

Numerous SARS-CoV-2 biosensor approaches have been
developed and reported recently. Magnetic beads, carbon black
electrodes and multiple antibodies were employed to achieve a
detection limit of 6.5 plaque forming units mL$^{-1}$ in whole
virus.$^{12}$ An ultrasensitive super sandwich-type assay has been
presented to detect viral RNA from SARS-CoV-2 with an LoD of
200 copies mL$^{-1}$,$^{13}$ and a FET biosensor capable of detecting
spike protein with a LoD of 242 copies mL$^{-1}$ in transport
medium has also been reported.$^{9}$ Plasmonic photothermal
biosensors have been shown to detect down to 0.22 pM of viral
RNA, which was estimated to be around $2.26 \times 10^4$ copies.$^{14}$
Other electrochemical sensors have also shown good sensitivity,
including molecular imprinted polymers (15 fM)$^{15}$ and graphene
and gold nanostars ($1.68 \times 10^{-22}$ µg mL$^{-1}$).$^{16}$ The sensor
developed here has comparable and clinically relevant sensitivity
(LoD for inactivated virus of 38.6 copies mL$^{-1}$), with a clear route
to manufacture. Importantly, the design of the sensor reported
here is resistant to mutations in the spike protein. In terms of
the chosen surface chemistry and the use of PFDT in a SAM
layer, there are examples in the literature of other sensor systems
with good anti-biofouling properties and these have been well
reviewed.$^{17}$ Demonstrations of anti-fouling properties in ternary
SAMs have recently been made$^{18,19}$ and there are advantages to
these approaches for more complex sensors. However, in our
experiments we could not reproduce the ACE2 insertion behaviour.
with standard hydrocarbon SAMs (Fig. S2, ESI†) and because of the emphasis on eventual sensor manufacture, PFDT was found to be well suited to the end application where monolayer coverage was sufficient to both retain the enzyme via amphiphobic interactions and provide anti-fouling properties.

Specificity of this sensor has been demonstrated against IL6, streptavidin, viral transport medium and one negative clinical saliva sample. This suggests that biofouling and non-specific binding of other commonly encountered biological proteins does not compromise assay sensitivity or specificity. Another consideration is other viral pathogens that bind to ACE2. Of the three viruses that are known to bind to ACE2, SARS-CoV-2 has the greatest affinity. SARS-CoV-1 is not present in the community and is therefore unlikely to impact the performance of this sensor. HCoV-NL63 primarily affects paediatric patient groups, which could limit the sensor to adult diagnostics if signal stratification is not possible. The current time to result based on the presented results is 30 min, which is competitive with existing SARS-CoV-2 assays but significant scope exists to reduce our assay time to faster sample turnaround times.

Further work will include sensor verification with a large set of samples to determine, (1) whether low, medium and high viral load SARS-CoV-2 samples can be stratified alongside HCoV-NL63 samples or whether positive vs negative is the only feasible assay output, (2) fully understanding the measurement artefact effects of surfactants and detergents from VPSS and VTM, (3) testing shorter incubation times to reduce the overall assay time to result below the current 30 minutes and (4) testing simpler electrochemical measurements (e.g. amperometry) to determine if more straightforward measurement circuits (and therefore a lower cost reader can be employed) than those required for impedance. These results present the basis of a novel, sensitive, selective and scalable biosensor assay which is based upon the principle of immobilising ACE2 into a layer with amphiphobic character. This sensor assay has sensitivity (1.68 ng mL−1) with recombinant spike protein and specificity against two proteins (IL-6 and streptavidin). When evaluated with a SARS-CoV-2 analytical grade laboratory inactivated virus kit, an LoD of 38.6 copies mL−1 was achieved. Finally, testing with high viral load clinical sample (Ct = 26) showed strong discrimination against a negative sample following inactivation in VPSS medium. Taking advantage of glucose biosensor production approaches (per sensor cost > £0.2) it is possible to demonstrate a clear path to translation through established manufacturing techniques, utilisation of existing sensor substrates and read out devices with prior CE marking. These findings together point towards a useful diagnostic tool, which can be rapidly deployed at low cost to screen for SARS-CoV-2 in a range of settings.

Conflicts of interest
There are no conflicts to declare.

Notes and references